BACKGROUND INFORMATION ON THE PROCEDURE 
1. 
Submission of the dossier 
The  applicant,  N.V.  Organon,  submitted  on  29  December  1998  an  application  for  a  Marketing 
Authorisation  to  the  European  Agency  for  the  Evaluation  of  Medicinal  Products  (EMEA)  for 
Orgalutran 0.25 mg / 0.5 ml solution for injection.  After agreement by the CPMP of 21-23 July 1998, 
this medicinal product is referred to Part B of the Annex to Council Regulation No (EC) 2309/93 of  
22 July 1993. 
The Rapporteur and Co-Rapporteur appointed by the CPMP were: 
Rapporteur:  Dr M. Toivonen 
Co-Rapporteur:   Dr H. van Bronswijk 
Licensing status: 
The product was not licensed in any country inside or outside the EU at the time of submission of the 
application. 
2. 
Steps taken for the assessment of the product 
• 
• 
• 
• 
• 
• 
• 
• 
• 
• 
• 
• 
• 
The procedure started on 29 January 1999. 
The Rapporteur's first assessment report was circulated to all CPMP Members on 1 April 1999. 
The  Co-Rapporteur’s  first  assessment  report  was  circulated  to  all  CPMP  Members  on  9  April 
1999. 
During the May 1999 meeting the CPMP agreed on the consolidated list of questions to be sent 
to the applicant. This was sent to the applicant on 19 May 1999.  
The applicant submitted the responses to the consolidated list of questions on 5 October 1999. 
The GMP inspection request was cancelled during the October CPMP meeting based on written 
clarifications from the applicant regarding quality issues. 
The  Rapporteur/Co-Rapporteur  circulated  the  response  assessment  report  on  the  applicant’s 
responses to the list of questions to all CPMP Members on 25 November 1999. 
The applicant gave an oral explanation on 14 December 1999 during the CPMP meeting and the 
remaining issues were presented by the company and discussed. 
The List of outstanding issues was adopted at the CPMP meeting on 14 December 1999. 
The applicant provided supplementary information on 6 January 2000. 
During the January 2000 meeting the CPMP, in the light of the overall data submitted and the 
scientific discussion within the committee, issued a positive opinion by consensus for granting a 
Marketing Authorisation to Orgalutran on 19 January 2000. 
During the January 2000 CPMP meeting a letter of undertaking has been adopted. 
The  CPMP  Opinions  were  forwarded,  in  all  official  languages  of  the  European  Union,  to  the 
European Commission, which adopted the corresponding Decisions on 17 May 2000. 
         1/1   
  EMEA 2004  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
